Biogen Idec (BIIB) Says CONFIRM Phase 3 for BG-12 Met Endpoints in Second Trial
Go back to Biogen Idec (BIIB) Says CONFIRM Phase 3 for BG-12 Met Endpoints in Second Trial| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 221.56 +9.01 (4.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $212.55 | 52 Week High | $333.65 | |||
| Open | $215.33 | 52 Week Low | $223.02 | |||
| Day High | $222.15 | P/E | 28.37 | |||
| Day Low | $215.08 | EPS | $7.81 | |||
| Volume | 880,802 | |||||
